Skip to content

Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients

Design of a Medical Device for Oxaliplatin-Induced Peripheral Neuropathy Considering the Patient's Voice in Gastrointestinal Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06873360
Enrollment
50
Registered
2025-03-12
Start date
2025-04-01
Completion date
2025-12-30
Last updated
2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Neuropathy Due to Chemotherapy

Keywords

Peripheral Neuropathy Induced by Oxaliplatin

Brief summary

This is an observational study related to a medical device designed for the prevention of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with gastrointestinal cancer. The primary objective is to collect data through interviews with patients experiencing OIPN symptoms to co-design the medical device prototype, incorporating the patient's perspective. Additionally, the study aims to identify clinical and usability patterns that will help optimize the design of a future clinical investigation assessing the safety and efficacy of the final device.

Detailed description

Main Hypothesis: The clinical data collected from patient interviews, along with their active participation in the co-design of the localized cooling medical device, likely in the form of gloves, will enable the design of both the functional prototype and the future clinical research on safety and efficacy. This approach will increase the likelihood of patient acceptance of the medical device treatment and help identify different patient profiles that could benefit the most from it. Secondary Hypotheses: 1. Patients will be able to easily adhere to the use of the device during chemotherapy. 2. The final glove design, in terms of materials and structure, will be suitable for commercial manufacturing and will have a viable demand among patients and healthcare providers. 3. There is no difference in treatment adherence between men and women or among people of different ages.

Interventions

OTHERClinical interviews with patients and Usability interviews and glove testing.

Clinical interviews with patients: These will be conducted by nursing staff with an approximate total of 50 patients during their treatment at the Hospital. Each interview will last 15 minutes. Under no circumstances will the patient be required to answer any question. Usability interviews and glove testing: 10 patients selected from the previous interviews will test different gloves with various textures and levels of stiffness. Additionally, other questions will be asked focusing on refining the design. This evaluation will help determine the most suitable materials for the device's manufacturing, achieving a balance between comfort, discretion and functionality.

Sponsors

Corporacion Parc Tauli
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Outpatient patient with gastrointestinal cancer treated with oxaliplatin. * Having completed at least three cycles of chemotherapy. * Presenting acute or chronic symptoms of chemotherapy-induced peripheral neuropathy. * The study will include individuals over 18 years old. Gender identify will be collected confidentially and inclusively, offering options for non-binary individuals and those who prefer not to identify with binary categories.

Exclusion criteria

* Patient with osteoarthritis or arthritis in the hands. * Diagnosis of any autoimmune disease affecting connective tissue, such as: rheumatoid arthritis, Raynaud's syndrome, lupus, scleroderma, dermatomyositis, vasculitis, or cryoglobulinemia.

Design outcomes

Primary

MeasureTime frameDescription
Co-design a medical device with patients to develop a solution that can prevent the onset of oxaliplatin-induced peripheral neuropathy (OIPN)From baseline to 6 monthsInterviews will be conducted with patients to gather information on the clinical presentation of oxaliplatin-induced peripheral neuropathy and its impact on patients' quality of life.

Secondary

MeasureTime frameDescription
Gain an in-depth understanding of the progression of OIPN symptoms.From baseline to 6 monthsIt consists of understanding the evolution of symptoms of oxaliplatin-induced peripheral neuropathy through quality of life questionnaires. These quality of life questionnaires will include questions related to intensity, location, triggers, and recurrence of these symptoms.
Ensure the usability of the device by assessing the patient's ability to adhere to treatment with a medical device.From baseline to 6 monthsThe patients will try different gloves with various textures and levels of stiffness. Additionally, other questions different from those in the main study will be asked, focusing more on refining the design. This evaluation will help determine the most suitable materials for the device's manufacturing, achieving a balance between comfort, discretion, and functionality.
Determine the design characteristics of the gloves.From baseline to 6 monthsThe patients will receive three different designs of non-functional commercial gloves (which do not generate cold or heat through electronics). In some cases, these gloves may have been modified to exhibit certain properties (such as texture, breathability, or thickness). Additionally, different sizes will be available for each model to ensure a proper fit for the patient's hand.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026